» Articles » PMID: 17242313

Renal Function and Risk of Hip and Vertebral Fractures in Older Women

Overview
Journal Arch Intern Med
Specialty General Medicine
Date 2007 Jan 24
PMID 17242313
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

Background: An increased rate of hip fractures has been reported in patients with end-stage renal disease, but the effect of less severe renal dysfunction on fracture risk is uncertain.

Methods: We conducted a case-cohort study within a cohort of 9704 women 65 years or older to compare baseline renal function (estimated glomerular filtration rate [eGFR] using the Cockcroft-Gault equation) in 149 women who subsequently had hip fractures and 150 women who subsequently had vertebral fractures with eGRF in 396 randomly selected women.

Results: In models adjusted for age, weight, and calcaneal bone density, decreasing eGFR was associated with increased risk of hip fracture. Compared with women with an eGFR 60 mL/min per 1.73 m(2) or greater, the hazard ratio (95% confidence interval [CI]) for hip fracture was 1.57 (95% CI, 0.89-2.76) in those with an eGFR 45 to 59 mL/min per 1.73 m(2) and 2.32 (95% CI, 1.15-4.68) in those with an eGFR less than 45 mL/min per 1.73 m(2) (P for trend = .02). In particular, women with a reduced eGFR were at increased risk of trochanteric hip fracture (adjusted hazard ratio, 3.93 [95% CI, 1.37-11.30] in women with an eGFR 45-59 mL/min per 1.73 m(2) and 7.17 [95% CI, 1.93-26.67] in women with an eGFR <45 mL/min per 1.73 m(2); P for trend = .004). Renal function was not independently associated with risk of vertebral fracture (adjusted odds ratio, 1.08 [95% CI, 0.61-1.92] in women with an eGFR 45-59 mL/min per 1.73 m(2) and 1.33 [95% CI, 0.63-2.80] in women with an eGFR <45 mL/min per 1.73 m(2); P for trend = .47).

Conclusion: Older women with moderate renal dysfunction are at increased risk of hip fracture.

Citing Articles

Real-world fracture risk, osteoporosis treatment status, and mortality of Japanese non-dialysis patients with chronic kidney disease stages G3-5.

Imanishi Y, Taniuchi S, Kodama S, Yoshida H, Ito T, Kawai R Clin Exp Nephrol. 2024; 29(2):236-247.

PMID: 39402308 PMC: 11828842. DOI: 10.1007/s10157-024-02562-y.


Incidence of new fractures in older patients with osteoporosis receiving biosimilar teriparatide or reference products: A retrospective cohort study.

Sato S, Sasabuchi Y, Okada A, Yasunaga H Br J Clin Pharmacol. 2024; 91(1):143-150.

PMID: 39245627 PMC: 11671314. DOI: 10.1111/bcp.16243.


Vertebral fractures in patients with CKD and the general population: a call for diagnosis and action.

Gifre L, Masso E, Fusaro M, Haarhaus M, Urena P, Cozzolino M Clin Kidney J. 2024; 17(8):sfae191.

PMID: 39099567 PMC: 11294886. DOI: 10.1093/ckj/sfae191.


Bone mineral density and related clinical and laboratory factors in peritoneal dialysis patients: Implications for bone health management.

Tamimi R, Bdair A, Shratih A, Abdalla M, Sarsour A, Hamdan Z PLoS One. 2024; 19(5):e0301814.

PMID: 38753845 PMC: 11098384. DOI: 10.1371/journal.pone.0301814.


Roles of Parathyroid Hormone and Fibroblast Growth Factor 23 in Advanced Chronic Kidney Disease.

Nakagawa Y, Komaba H Endocrinol Metab (Seoul). 2024; 39(3):407-415.

PMID: 38752265 PMC: 11220210. DOI: 10.3803/EnM.2024.1978.